In a syngeneic pancreatic cancer mouse model, anti-CD40 mAb treatment resulted in the intra-tumoural migration of hyperinflammatory monocytes and macrophages, which mediated tumour regression [114]. Here, CD40 is linked to familial pancreatic carcinoma.